Analýza mikroRNA u extramedulárního relapsu mnohočetného myelomu
| Title in English | MicroRNA analysis for extramedullary multiple myeloma relapse |
|---|---|
| Authors | |
| Year of publication | 2018 |
| Type | Article in Proceedings |
| Conference | XLII. brněnské onkologické dny a XXXI. konference pro nelékařské zdravotnické pracovníky |
| MU Faculty or unit | |
| Citation | |
| Keywords | multiple myeloma; microRNA; NGS |
| Description | Introduction and aims: Multiple myeloma (MM) is the second most common hematooncological disease. Patient survival has been greatly improved by the introduction of new drugs into clinical practice, but survival is negatively affected by the so-called extramedullary relapse (EM), caused by the loss of plasma cell dependence on the bone marrow microenvironment and their migration out of the bone marrow. The nature and causes of this process are currently unclear. MicroRNAs (miRNAs) are short, non-coding RNA molecules involved in many physiological and pathological processes. Their significance in the pathogenesis of multiple myeloma has been demonstrated by several studies. We assume that they are also involved in the development of the EM. The aim of this study was to analyze different miRNA expression between MM and EM patients. Material and Methods: Using next generation sequencing (NGS), we analyzed 39 samples of bone marrow cells from MM patients at diagnosis and 9 bone marrow plasma samples of EM patients. Results: In total, 2278 miRNA were sequenced, but only 658 miRNAs were analyzed as they were expressed in all samples and had at least 20 reads. Expression data were generated using the Chimira tool from fastq data. All sequences were mapped using miRBase v20. Further analyses were performed using the R / Bioconductor package. The Bayesian procedure was used for normalization of expression. P values were adjusted using the Benjamini-Hochberg method. Analysis found 10 miRNA (p <0.0005) that are statistically significantly expressed in EM vs. MM patients - these are: miR-26a-5p, miR-26b-5p, miR-30e-5p, miR-424-3p, miR-503-5p, miR-767-5p, miR-105-5p, miR-5695 -5p, miR-450b-5p, miR-92b-3p. These miRNAs will be further verified by qPCR method on a larger set of MM and EM patients. Conclusion: Our pilot study has shown that there are differentially expressed miRNAs between MM and EM patients. |
| Related projects: |